NASDAQ:IDIX - Idenix Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Idenix Pharmaceuticals, Inc. (Idenix) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. As of December 31, 2012, the Company's primary research and development focused on the treatment of patients with hepatitis C virus (HCV). In June 2012, the Company completed a three-day proof-of-concept study designed to evaluate 64 treatment-naive HCV genotype 1, 2, 3 or 4-infected patients. In July 2012, the FDA granted Fast Track designation for IDX719. The Company, as of December 31, 2012, was developing nucleotide polymerase inhibitors and NS 5A inhibitors to inhibits HCV replication, which include nucleoside/nucleotide polymerase inhibitors and NS5A Inhibitors. On January 25, 2013, the Company entered into a non-exclusive collaboration agreement with Janssen Pharmaceuticals, Inc for the clinical evaluation of all oral DAA HCV combination therapies.

Receive IDIX News and Ratings via Email

Sign-up to receive the latest news and ratings for IDIX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Current SymbolNASDAQ:IDIX



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable

Idenix Pharmaceuticals (NASDAQ:IDIX) Frequently Asked Questions

What is Idenix Pharmaceuticals' stock symbol?

Idenix Pharmaceuticals trades on the NASDAQ under the ticker symbol "IDIX."

Has Idenix Pharmaceuticals been receiving favorable news coverage?

Press coverage about IDIX stock has trended positive recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Idenix Pharmaceuticals earned a coverage optimism score of 2.6 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an impact on the stock's share price in the immediate future.

What other stocks do shareholders of Idenix Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Idenix Pharmaceuticals investors own include Ariad Pharmaceuticals (ARIA), Arena Pharmaceuticals (ARNA), Gilead Sciences (GILD), VIVUS (VVUS), Dendreon (DNDNQ), Rio Tinto (RIO), Achillion Pharmaceuticals (ACHN), Aegerion Pharmaceuticals (AEGR), AEterna Zentaris (AEZS) and Amarin (AMRN).

How do I buy shares of Idenix Pharmaceuticals?

Shares of IDIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Idenix Pharmaceuticals' official website?

The official website for Idenix Pharmaceuticals is

How can I contact Idenix Pharmaceuticals?

Idenix Pharmaceuticals' mailing address is 320 Bent St, CAMBRIDGE, MA 02141-2025, United States. The biopharmaceutical company can be reached via phone at +1-617-9959800.

MarketBeat Community Rating for Idenix Pharmaceuticals (NASDAQ IDIX)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  158 (Vote Outperform)
Underperform Votes:  189 (Vote Underperform)
Total Votes:  347
MarketBeat's community ratings are surveys of what our community members think about Idenix Pharmaceuticals and other stocks. Vote "Outperform" if you believe IDIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IDIX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/20/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel